Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension

Journal of the American Geriatrics Society

Volumn 53, Issue 11, 2005, Pages 1996-2000

  Schellenbaum, Gina D ^a,c   Smith, Nicholas L ^a   Heckbert, Susan R ^a   Lumley, Thomas ^a   Rea, Thomas D ^a   Furberg, Curt D ^b   Lyles, Mary F ^b   Psaty, Bruce M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

ACE inhibitors; Aging; Congestive; Heart failure; Hypertension; Weight loss

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ELDERLY CARE; FEMALE; GRIP STRENGTH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE STRENGTH; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HAND STRENGTH; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; STATISTICS; UNITED STATES; WEIGHT LOSS;

EID: 29244445119     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53568.x     Document Type: Article

References (12)

1. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053.
2. Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: An observational study. Lancet 2003;361:1077-1083.
3. Newman AB, Yanez D, Harris T et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001;49:1309-1318.
4. Fried LP, Ferrucci L, Darer J et al. Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59A:M255-M263.
5. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
6. Onder G, Penninx BW, Balkrishnan R et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study. Lancet 2002;359:926-930.
7. Fried LP, Borhani NO, Enright P et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991;1:263-276.
8. Ives DG, Fitzpatrick AL, Bild DE et al. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study. Ann Epidemiol 1995;5:278-285.
9. Smith NL, Psaty BM, Heckbert SR et al. The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol 1999;52:143-146.
10. Peeters AC, Netea MG, Kullberg BJ et al. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology 1998;94:376-379.
11. Moldawer LL, Copeland EM 3rd. Pro inflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997;79:1828-1839.
12. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003;196:171-179.